Document is current
Any future updates will be listed below
-
Authors
Ludwig, Heinz
Mai, Elias K.
Högner, Marion
Welslau, Manfred
Waldschmidt, Johannes M.
- License Information
-
More Information
Article History
Received: 22 July 2025
Accepted: 22 September 2025
First Online: 10 November 2025
Declarations
:
: H.L: Research Support: Sanofi, Amgen. Speakers Bureau/Advisory Boards: Janssen, Sanofi, Pfizer, GSK, Pfizer, OncopeptidesE.K.M: Advisory Board: Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Oncopeptides, Sanofi und Takeda. Honoraria: Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Oncopeptides, Sanofi und Takeda. Research Funding: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi und Takeda. Travel expanses: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini Stemline, Pfizer, Sanofi und TakedaM.H. received payments for Advisory boards or travel grants from Jansen Cilag, Sanofi Aventis, Oncopeptides, Takeda Oncology, Pfizer OncologyM.W.: Advisory board: Amgen, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, Lilly, Medac, Novartis, Roche, Sanofi, Astra Zeneca, Oncopeptids. Honoraria: Amgen, Astellas, AstraZeneca, Celgene, Gilead, Hexal, Janssen, Lilly, Novartis, Roche, Sanofi, Daichii-Sankyo, OncopeptidsJ.M.W. has consulted for Johnson&Johnson, BMS, Sanofi, Take¬da, Pfizer, Oncopeptides and Skyline Dx; received honoraria from Takeda, GSK, Pharmamar and Beigene; and received research support from BMS.
